In this phase 3 study, researchers sought to determine whether the addition of palbociclib may overcome resistance to endocrine and HER2-directed therapies.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Palbociclib plus ...

Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...

Female patient on hospital bed. Palbociclib added to adjuvant endocrine therapy failed to improve iDFS. The following article features coverage from the 2021 San Antonio Breast Cancer Symposium. Click ...

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a ...

Please provide your email address to receive an email when new articles are posted on . Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and ...

First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...

MUNICH -- Median survival in advanced hormone receptor-positive (HR+) improved by as much as 10 months in patients who received the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) in ...

PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to ...

Please provide your email address to receive an email when new articles are posted on . The addition of 1 year of palbociclib to endocrine therapy failed to improve invasive DFS among women with ...

Credit: Getty Images. Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast ...